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Abstract
Background: Patients with unmet medical needs sometimes resort to non-standard treatment options, including
the use of unapproved, investigational drugs in the context of clinical trials, compassionate use or named-patient
programs. The views and experiences of patients with unmet medical needs regarding unapproved, investigational
drugs have not yet been examined empirically.
Methods: In this qualitative study, exploratory interviews and focus groups were held with patients with chronic or
life-threatening diseases (n = 39), about topics related to non-standard treatment options, such as the search for
non-standard treatment options, patients’ views of the moral obligations of doctors, and the conditions under
which they would or would not wish to use non-standard treatment options, including expanded access to
unapproved, investigational drugs.
Results: Respondents had very little knowledge about and/or experience with existing opportunities for expanded
access to investigational drugs, although some respondents were actively looking for non-standard treatment options.
They had high expectations of their treating physicians, assuming them to be aware of non-standard treatment
options, including clinical trials elsewhere and expanded access programs, and assuming that they would inform their
patients about such options. Respondents carefully weighed the risks and potential benefits of pursuing expanded
access, citing concerns related to the scientific evidence of the safety and efficacy of the drug, side effects, drug-drug
interactions, and the maintaining of good quality of life. Respondents stressed the importance of education and
assertiveness to obtain access to good-quality health care, and were willing to pay out of pocket for investigational
drugs. Patients expressed concerns about equal access to new and/or non-standard treatment options.
Conclusion: When the end of a standard treatment trajectory comes into view, patients may prefer that treating
physicians discuss non-standard treatment options with them, including opportunities for expanded access to
unapproved, investigational drugs. Although our respondents had varying levels of understanding of expanded access
programs, they seemed capable of making well-considered choices with regard to non-standard treatment options
and had realistic expectations with regard to the safety and efficacy of such options. Dutch patients might be less likely
to fall prey to false hope than often presumed.
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Background
Patients have unmet medical needs when adequate treat-
ment options are not – or no longer – available for their
condition. Sometimes, patients with unmet medical
needs may wish to look beyond standard treatment op-
tions, and may be eligible to try investigational drugs:
new drugs that are not yet approved for marketing and
are still under investigation. Access to investigational
drugs will usually be possible only in the context of a
clinical trial. However, when seriously ill patients who
have exhausted standard treatment options1 cannot be
enrolled in clinical trials, their doctors might consider
‘expanded access’ to investigational drugs.
In many countries, expanded access can be requested
for individual patients, through so-called ‘named-patient’
programs, or for groups of patients, in so-called ‘com-
passionate use’ programs. The latter are often initiated
by pharmaceutical companies after the successful com-
pletion of phase III clinical trials, to bridge the gap be-
tween the trial and the commercial launch of the new
drug. The company usually supplies the drug for free.
Individual- or named-patient expanded access is often
initiated by treating physicians in ‘back against the wall’
situations. The physician will need to ask the pharma-
ceutical company to release the investigational agent,
and to request a drug regulatory authority to approve
the request for ‘named-patient’ usage of the unapproved
drug. Through named-patient programs, drugs may be
provided earlier in the drug development process, after
completion of phase I or IIa clinical trials. In some coun-
tries, including the United States of America (USA),
Spain and Italy, and in some hospitals in the United
Kingdom, approval from a research ethics review com-
mittee or institutional review board is mandatory [1, 2].
In countries where expanded access is not reimbursed,
the uptake is generally very low.
It is believed that health literate, high-income and
well-connected patients are likelier to succeed in obtain-
ing access to investigational drug outside of clinical trials
than other patients [1, 3]. In many countries, few physi-
cians actively engage with expanded access, which likely
results from both ethical concerns and the many hurdles
that must be overcome in order to obtain investigational
drugs: the paperwork, the time, funding and the uncer-
tainty regarding the outcome [2]. Consequently, many
doctors are not aware of opportunities for expanded ac-
cess or have little personal experience with it [4], and
may not bring it up as a possibility when their patients
run out of standard treatment options. It is estimated
that doctors submit around a thousand requests for ex-
panded access for individual patients to the Food and
Drug Administration (FDA) in the USA annually [5], for
instance, and between 100 and 200 requests annually in
the Netherlands [6], although it should be noted that
based on one approved request, doctors may prescribe
the treatment for multiple (similar) patients.
Various groups around the world, however, are trying
to change this, by raising awareness of expanded access
and/or facilitating its processes. In the USA, for instance,
the Right-To-Try group has successfully campaigned for
a federal law allowing seriously ill patients to use un-
approved drugs without the need for authorization by
the FDA [7]. While this legislation has been heavily criti-
cized by legal experts and bioethicists alike [8, 9], its
popularity signals public support for the general idea
that patients should be allowed to access unapproved
drugs if nothing else is available. Furthermore, as pa-
tients and patient advocacy groups can now easily access
scientific publications online, they are becoming more
knowledgeable about drug development activities around
the world. Drug development usually takes a long time
[10], and patients are not always patient. In Europe, after
a drug has been approved centrally by the European
Medicines Agency (EMA), it may not be available within
the healthcare system until national authorities have
made reimbursement and pricing decisions, which can
take up to a year [11]. Patients who have exhausted
standard treatment options and are facing life-
threatening illness may wish to access the new drug
sooner. As a result, demand among patients for ex-
panded access (through named-patient or compassionate
use programs) may be rising [5].
These developments have raised ethical issues on vari-
ous levels, which have been discussed elsewhere [12, 13].
With regard to individual patients, the most pertinent
ethical issues include the uncertainties regarding the
safety and efficacy of the incompletely tested drug, the
vulnerable position that patients with unmet medical
needs may find themselves in, concerns related to the
exploitation of patients’ hopes and the associated diffi-
culties of obtaining informed consent. These issues are
often brought up by experts, however, not patients
themselves.
To our knowledge, no empirical research has thus far
been directed at patients’ views of - and experiences with
- expanded access. Little is known about patients’ aware-
ness of opportunities for access to unapproved,
1When we use the term ‘standard treatment options’ in this paper, we
are referring to treatment options that are curative or life prolonging
and that are part of standard of care and/or incorporated in clinical
guidelines for specific diseases or disorders. Palliative treatment
options can also be part of standard of care and/or incorporated in
clinical guidelines, but is aimed at the improvement of quality of life,
not at a cure.We take the term ‘non-standard treatment options’ to
refer to treatment options that are off-label, not (yet) approved for
marketing, investigational, and being studied in clinical trials or pre-
scribed within expanded access programs, including named-patient
and compassionate use programs. They are not part of standard of care
and are not (yet) incorporated in clinical guidelines in the Netherlands.
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investigational treatment options, their motivations for
pursuing non-standard treatment options or not pursu-
ing such options, or the obstacles encountered by pa-
tients in the process of seeking information about non-
standard treatment options, talking about such options
with their treating physicians, or requesting access. In
the context of this qualitative study, interviews and focus
groups have been conducted with Dutch patients suffer-
ing from serious chronic or life-threatening diseases to
learn about their experiences - if any - with expanded
access to unapproved, investigational drugs, and about
their concerns, preferences and expectations with regard
to non-standard treatment options, when the end of a
standard - curative or life prolonging - treatment trajec-
tory comes into view.
In the Netherlands, the same set of formal condition
applies to expanded access as in many other health care
systems: patients must suffer from serious and/or life-
threatening illness, must have exhausted standard treat-
ment options, and must not be eligible for participation
in clinical trials. There are two distinct routes to ex-
panded access: 1) individual requests for the named-
patient program, for which treating physicians usually
collaborate with hospital-based pharmacists, and which
are evaluated by the Health Inspectorate, and; 2) com-
passionate use programs, initiated by pharmaceutical
companies, to which treating physicians apply directly
for release of the drug for individual patients or groups
of patients, and which are evaluated by the Dutch Medi-
cines Evaluation Board. In the Netherlands, hospitals do
not usually accept out-of-pocket payment from patients
and usually and offer medical care that is covered by
health insurance. Thus, expanded access can generally
only take place if the pharmaceutical company supplies
the investigational agent at no cost, if the hospital is will-
ing to pay for the drug or (in rare cases) if a health in-
surer is lenient and willing – by exception – to cover the
costs of the treatment. The uptake of the named-patient
program is an estimated 100–200 requests annually in a
population of over 17 million. Evaluation by a research
ethics review committee or institutional review board is
not required in the Netherlands. Although Dutch regula-
tory routes to expanded access differ in some respects
from those in other countries, many of the themes dis-
cussed are of relevance to systems for expanded access
in other countries, as well.
Methods
To map patients’ experiences with and views of ex-
panded access to investigational, unapproved drugs, we
held exploratory interviews and focus groups with pa-
tients with potentially unmet medical needs. The Re-
search Ethics Review Committee of Erasmus MC
evaluated the protocol and provided a waiver (MEC-
2016-275). All interviews and focus groups were held in
Dutch.
Focus groups
In total, five focus groups were conducted, each with 6–
7 participants (in total: 34 participants), four focus
groups with patients who were representative of the gen-
eral patient population in the Netherlands and one focus
group with ‘expert patients’. As we expected, based on
the literature, that patients’ experiences with expanded
Fig. 1 The various stages patients may journey through after they run out of standard treatment options
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access would be limited, we developed an interview
guide (see Additional file 1) in which we successively
discussed standard of care and to what extent patients
were aware of a standard of care and actively sought in-
formation about standard and non-standard treatment
options. We discussed steps that are taken when stand-
ard treatment options are no longer available or do no
longer suffice: referrals to medical specialists working in
tertiary care or centers of expertise within university
medical centers, second opinions, participation in clin-
ical trials, and expanded access. Thus we discussed the
various more or less chronological stages in which pa-
tients would be confronted with standard or non-
standard treatment options [14, 15], converging toward
the use of unapproved drugs (see Fig. 1). We anticipated
that fewer and fewer participants would have personal
experience with each consecutive stage, like a funnel. Pa-
tient journeys may also follow different routes, but dur-
ing the focus groups, we used this funnel as a directive
guide.
Alongside this funnel, patients may seek or be con-
fronted with non-standard treatment options such as al-
ternative and complementary treatments or ‘experimental’
therapies offered through questionable for-profit providers
in foreign countries. During our focus groups, we made
clear to respondents that such treatment options were not
within the scope of our discussion.
Through open-ended questions, we encouraged pa-
tients to put forward experiences, views or narratives
that they themselves considered important with regard
to access to (non-standard) medical treatment. When we
discussed the topic of expanded access, we asked partici-
pants to consider questions in silence and write down
their answers on a piece of paper (i.e. ‘Under what con-
ditions would you consider trying an unapproved, inves-
tigational drug?’, ‘What would be reasons for you to try
(or to not try) a new drug?), before we continued with
the discussion. When we asked respondents under what
conditions they would be willing to try an investigational
drug, we explained clearly that we were talking about
drugs under clinical investigation, for which there was
some - but not sufficient - evidence of safety and effi-
cacy, and which have not been approved for marketing.
For the first four focus groups, we asked a recruitment
agency (CG Selecties) to invite participants from a repre-
sentative sample of Dutch inhabitants of the Rotterdam
region and the Amsterdam region, including surround-
ing smaller towns and cities. We held two focus groups
in Rotterdam at Erasmus MC in September 2016, and
two focus groups in Amsterdam in a public library in
October 2016. Two focus groups were held in the after-
noon, and two focus groups were held in the evening
hours. All focus groups lasted 2 h at minimum. For each
focus group, 7 participants were invited. The invitation
stated that the researchers were looking for people suf-
fering from a chronic and/or serious disease or condition
for which they use or have used medications. Partici-
pants were offered 50 euros to cover their travel costs
and other expenses. These focus groups are from now
on referred to as F1 to F4 (focus groups 1 to 4) when
quoted.
The fifth focus group comprised six respondents who
were patients, but also active members or founders of
patient organizations, and can be thought of as ‘expert
patients’. ‘Expert patients’ have been defined as patients
“who (have) been empowered with the skills, confidence
and knowledge needed to play an active role in making
decisions about their own health care and management
of their chronic condition” [16]. Expert patients are both
active participants in the self-management of their dis-
ease and health literate. Therefore, they are not repre-
sentative of the general patient population, where health
literacy may be more limited [17]. The focus group was
held at Erasmus MC in July 2016, and lasted 2 h. Re-
spondents were recruited through a representative of the
Dutch Federation of Cancer Patients (NFK), who was in-
volved in the research project as a stakeholder. When
presenting results from this focus group, it is referred to
as FE (focus group experts).
Interviews
Semi-structured interviews were held with 5 individual pa-
tients, who were sampled purposively either through
members of our valorization panel2 or through other con-
tacts. We actively sought patients who may have had per-
sonal experiences with expanded access. The same
interview guide was used for the interviews. The inter-
views were meant to yield personal narratives and more
in-depth insight in the experiences of patients who (may)
have used unapproved drugs. It should be noted that most
of these patients should also be considered experts pa-
tients. Patients were Dutch and from the same or similar
regions in the Netherlands as F1–4 respondents. Inter-
views were conducted over Skype, at Erasmus MC or at
patients’ homes, and lasted between 1 and 2 h. When
2A ‘valorization panel’ consists of stakeholders who offer feedback on
the research questions, approach and results, and assist with the
dissemination of the research results. Our valorization panel included
representatives of patient organizations, physicians’ organizations,
(hospital-based) pharmacists’ associations, trade associations for the
pharmaceutical industry, and regulatory and health technology
assessment authorities. The set-up of a valorization panel is a require-
ment of the Responsible Innovation program at the Netherlands Or-
ganisation for Scientific Research, which funded the research project
(https://www.nwo-mvi.nl/showcase/value-valorisation-panel). The
valorization panel serves as a counterweight to the collaboration with
one or more private partners (in our case, myTomorrows), another
central requirement of the Responsible Innovation program.
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quoted, the interviews are referred to as I1 to I5 (inter-
views 1 to 5).
Analyses
Focus groups and interviews were audio-recorded and
integrally transcribed verbatim. NVivo 10 and 11 were
used as tools to systematically code the data. The au-
thors (EB, NA) independently coded (the same) three
transcripts and developed codebooks by creating, group-
ing and re-grouping codes into hierarchies or themes.
Coding and codebooks were compared and differences
were discussed and resolved. After EB coded more tran-
scripts, the researchers again independently coded a
transcript and discussed and resolved any differences.
Remaining transcripts were coded by EB, and were all
thematically analyzed to provide qualitative description
[18] of patients’ views and experiences. Quotes were se-
lected and translated to English by EB.
Results
Respondents
The focus groups in Rotterdam were attended by 14 par-
ticipants in total (13 women, 1 man), whose ages ranged
from 22 to 63 (median age: 50). In Amsterdam, the focus
groups were attended by 14 participants (7 men, 7
women), whose ages ranged from 19 to 79 (median age:
62,5). Eighteen participants had received lower or higher
secondary education, 8 had received higher vocational
education, and 2 had attended universities. The majority
of participants did not have paid jobs (n = 23): some
were declared unfit for work (n = 6), looking for employ-
ment (n = 3), or retired (n = 6). Some participants did
voluntary work, and one was a student. Five participants
had paid jobs. Some participants lived in the city, some
in smaller towns in the region.
All participants used or had used pharmaceutical medi-
cations. Patients suffered from cancer of the brain, skin,
breast, bladder or larynx, neuromuscular disorders (mul-
tiple sclerosis, myasthenia gravis, epilepsy), rare diseases
or conditions (cryoglobulinemia, Addison’s disease, Con-
genital Ichthyosiform Erythroderma) or chronic diseases
or conditions (chronic obstructive pulmonary disease, dia-
betes mellitus, rheumatism, rheumatoid arthritis, Crohn’s
disease, hypothyroidism, epilepsy, cardiac arrhythmia,
ocular herpes, auto-immune hepatitis, familial hyperchol-
esterolemia, chronic depression, fibromyalgia). Many par-
ticipants had multiple conditions.
In our focus group with expert patients, some partici-
pants underlined at the outset that they spoke not only
about themselves, but also on behalf of dozens or hun-
dreds of other patients. Some indicated that they differed
from ‘the average patient’ in many respects, including
knowledge level and understanding of the disease and
treatment options, and the ability to cope psychologically
with their (past) disease. Three patients were female, three
were male. All patients were oncology patients, having
been diagnosed with (metastasized) colorectal, breast,
prostate and pharyngeal cancer, neuroendocrine tumors
and melanoma. Respondents of our individual interviews
ranged in age between 46 and 66, two were male and three
were female. Patients had been treated for breast cancer (2
respondents), colon cancer, prostate cancer or renal can-
cer. Respondents of F1–4 did not have first-hand experi-
ences with expanded access. Some respondents of FE and
individual interviews did have first-hand experience with
expanded access.
Themes
Six key themes were identified based on our discussions
with patients about non-standard treatment options, and
will be presented below: experiences with standard of
care, patient assertiveness, the patient’s search for other
options, reasons (not) to pursue non-standard treatment
options, patients’ expectations of physicians with regard
to other non-standard options, and reimbursement of
non-standard treatment options. The themes are pre-
sented in a roughly (chrono) logical order following the
scheme in Fig. 1. In all themes, the doctor-patient rela-
tionship plays a prominent role.
Experiences with standard of care
The topic of access to medical care elicited immediate
reactions in focus group participants, which, we ob-
served, many of them had a desire to share. Although
we did not ask any specific questions about this topic, in
all five focus groups, respondents spontaneously offered
narratives about medical mistakes and mishaps. Diagno-
ses were missed, including fractures, solid cancers, infec-
tions, and appendicitis; mammography images had got
lost; doctors had continued with off-label treatment of
an autoimmune disease despite serious side effects; a
major operation had to be postponed last-minute be-
cause of a pre-screening error; one patient suffered from
serious long-term neuropathy problems as a result of a
preventable complication; a skin lesion was removed by
a befriended primary care surgeon but not sent in for
pathological examination, and later turned out to be
melanoma, by then metastasized; and artifacts on MRI
or CT that later proved not to be metastases, implying
that the patient was not going to die after all. Despite
these negative experiences, respondents expressed a cer-
tain degree of understanding and acceptance; health pro-
fessionals, like other human beings, make mistakes. This
was thought of as normal. Doctors have to be jacks-of-
all-trades, it was felt: when they must excel at diagnosis
and surgery or pharmaceutical treatment and communi-
cation with patients, they will be fallible at times.
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Respondents did not usually issue any formal complaints
or take any legal steps:
So afterwards I did send a letter to the board of the
hospital. And I wrote: this is not a complaint. This is a
suggestion for improvement. Because I think it is too
easy just to issue complaints. These people, they are
trying to do the right thing, that is what I expect. And
they all have their professional ethics; they are trying
to help patients get better. And things do go wrong.
But where in society don’t things go wrong? I think you
have to try constructively to guide them. Not by
complaining, but by showing them how you would like
to have things. (FE).
Although we, likewise, did not intend to elicit respon-
dents’ appraisals of the attitudes of their treating physi-
cians, focus group discussions did tend to take this turn
and centered around patients’ views of the doctor-
patient relationship. Overall, respondents were positive
about their doctors. Patients valued a helpful and guid-
ing attitude in their primary care physicians, and liked it
when their doctors gave them the feeling that they had
“all the time in the world” (F1), that they had the time to
explain things and to talk to patients. Respondents
wanted their doctors to show compassion, to see and
treat them like human beings. Also, they wanted physi-
cians to be accessible, through email or telephone. One
respondent mentioned, for instance, how she appreci-
ated that she could always pick up the phone and if
needed, she could go see her doctor “within 15 minutes”
(F3). Another patient spoke with gratitude of a doctor
who, one night, had remained with him and his dying
wife until four o’clock in the morning (F3). Patients also
valued honesty and truthfulness, and appreciated it when
doctors showed that they, too, had their limitations and
were not omniscient:
I am lucky, because I hear a lot of horror stories from
people around me about their primary care physicians,
but I am lucky because mine is always collaborative.
And if I come with something, he will, together with
me, look at it seriously. And he’ll say: ‘I don’t know,
I’m going to find out.. and sometimes I am even there
in the room, and he’ll call a medical specialist to
check something. Or he’ll just grab a book to look
something up. (F1).
So I see this internist and he tells me what I’ve got.
And he says: ‘I don’t know anything about this disease.
I’ve been looking it up,’ he says, ‘but I’ll go and learn
about it’. And he’s been in contact a lot with doctors
in the USA. And this guy has been learning about this
condition.. Well, he is now the only one in the
Netherlands who knows exactly what it is. He has
really been absorbed by the whole story. That’s why
I’m so happy with him. (F3).
Some respondents, however, were negative about some
of their doctors’ attitudes. In their experience, many
doctors did not have time to talk, to listen or to explain
things, and would only have 5 or 10min for their pa-
tients. Respondents also felt that doctors were not al-
ways equipped with social or communicative skills,
showed little interest in their patients’ experiences, had
trouble making contact, and did not understand that not
all patients were the same. Some doctors were impolite,
blunt or hurtful:
So I go see the surgeon who had done the operation
and he says: ‘You’ve got cancer’. And then he turns to
the assistant and says: ‘Will you take it from here?
Help these people to a glass of water. Because I have to
continue with my consultations.’ That was my health
care. (FE).
Well, it is the nurses who do all the work, putting that
thing in your bladder, and the doctor is running from
one room to the next. And then he’s gone. You can
never ask him anything.. Get him to explain anything?
No. (F3).
At times, negative experiences with treating physicians
were a reason for respondents to start looking for other
options, and seek referral or second opinion within the
Netherlands, or even treatment abroad. Patients’ jour-
neys towards expanded access start against the backdrop
of their experiences with standard of care.
Patient assertiveness
Respondents felt that, often, at their hospitals, they
were not able to access other treatment options than
standard of care: they had to take initiative to get a
referral or a second opinion and/or they had to seek
information about clinical trials themselves, for their
doctors would not mention trials. Respondents felt
that it is important for patients to learn about their
own conditions, to increase their health literacy, to
take steps to inform and empower themselves. Pa-
tients need to be alert for medical errors or negli-
gence, and to be assertive and ask for diagnostic tests
and/or best available treatment options. Respondents
stressed that they had to argue and to push for what
they wanted or needed:
So I ended up in a cast for half a year, and that has
taught me to just be so, so enormously alert to the
signals within your body. And to just not accept
Bunnik and Aarts BMC Medical Ethics           (2019) 20:80 Page 6 of 17
whatever it is that doctors are telling you. If you think
‘this is wrong’, well, you have to push on. (F2).
By now [medical erros] have happened to me so
many times that I am not taking any nonsense
anymore. I will tell [healthcare professionals]
exactly what I feel and what I think, especially now
with this melanoma. If I see a doctor and am told
‘Oh, no, probably nothing is wrong’, I now tell them:
‘Please take a biopsy of this lesion’. That’s it. And I
don’t want to go and sit in any doctor’s chair, but
if I ever get another medical error… (F1).
Also, patients reported that doctors sometimes sug-
gested clinical management that they did not agree with,
and that they experienced little freedom to depart from
standard of care. Many respondents were aware of pro-
tocols or standard treatment trajectories, and felt that
physicians directed them towards or within those proto-
cols in ways that did not align with their own prefer-
ences and treatment objectives:
R. Because they want you in a trajectory, it happened
to me, too, because you are a number and you have to
be in this trajectory. […].
R. Because of this breast cancer, you enter a trajectory.
And that means that you get chemotherapy, and after
that radiotherapy.
R. Right.
R. And then you get a conversation and I said: ‘No, I
don’t want that.’ At first they were very friendly and
they gave me a week to think it over, and I said: ‘No, I
don’t want chemotherapy or radiotherapy.’ And then
they stopped being friendly. Because I turned down
that trajectory. (F1).
Education and empowerment were considered im-
portant in order to maintain control and self-
determination within health care. A respondent with
breast cancer said:
If I want to be the director of my health care, then I
want to have moments of choice. I want to have
information, and I want to be able to press a button to
say ‘stop’. And, well, we don’t have that now, and
there is a lot of work to do. I for instance would like to
be present at my own multidisciplinary team meeting.
But I can’t. (I2).
Many of our respondents had experienced problems
with access to standard of care, notably with referrals
to the ‘right’ medical specialist. Though some patients
had been adequately and rapidly referred to medical
specialists such as dermatologists, cardiologists or on-
cologists in either regional or academic hospitals,
others had less positive experiences with referrals. Pa-
tients were not always referred to tertiary care or ex-
pertise centers, when they themselves did deem this
necessary. In the Netherlands, phase I clinical trials in
oncology are generally offered only in university med-
ical centers or specialized centers [15], to which phy-
sicians working in peripheral hospitals would have to
refer. Respondents did not feel that doctors have fi-
nancial incentives not to refer. Many doctors in the
Netherlands are salaried employees and are not paid
per patient or service offered. Rather, to our respon-
dents, physicians’ hesitance to refer was best ex-
plained by professional pride:
R: But doctors don’t even refer for trials in other
hospitals. That’s where the problem starts […]. If
doctors do not refer to opportunities outside their own
hospitals, even though, for instance, there are trials
available elsewhere, it they don’t even do that…
I: Do others too have the impression that doctors don’t
refer to other centers?
R: Very many doctors don’t.
R. No, that happens very rarely.
R: I think doctors don’t do that. They all have a little
bit of professional pride. And they want to fix [the
patient] themselves. (FE).
Expert patients believed that 50% of patients are ac-
tively counteracted by doctors when seeking referral
care. Some patients reported that it took a long time
for them to get a diagnosis, especially in cases of rare
diseases. Patients felt that their doctors did not take
seriously their complaints, and spoke of ‘diagnostic
Odysseys’. A respondent with a rare disease said:
On the other hand, because you know so much about
[your own condition], you won’t let them send you
away, and at the primary care physician it takes a
very long time before you are taken seriously. […] You
know, with primary care physicians, they are quick to
think that something is wrong psychologically. You
really have to say: and now I want you to refer me to
someone. That I deplore sometimes. (F1).
I have had serious neurological problems since 2012,
but I don’t know what is wrong. […] In the
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Netherlands it is very difficult to get diagnosed. You
have to fight for years. And they want to send you to a
psychologist first. It all goes very slowly, in fact, to
come to a diagnosis. (F3).
Respondents stressed that they had to take their treat-
ment into their own hands. They were the ones that ac-
tively searched for treatment options when standard of
care did not suffice. Often, they had to convince their
doctors to try and use new possibilities. A patient who
went abroad for a privately funded unapproved, investi-
gational treatment said:
R. The patients who are now being treated with
[an investigational treatment], those are all patients
for whom the question has come up from the inside,
through the patient organization. And, well, I myself
started this discussion, and I now know six, seven
people who are all in this network, and I started
this discussion with my doctor. And he will respond
to [our wish to try this investigational treatment]…
But he never brought it up himself. He never…
He will not suggest something that he is not
offering. (I3).
The patient’s search for other options
Many of our respondents with chronic diseases actively
participated in mapping out their treatment plan. On-
line, they searched for information about their condition
and potential investigational treatment options. When
they came across information about new treatments for
their condition in newspapers or magazines, or on televi-
sion, they pursued those leads and brought them up at
their next doctor’s appointments.
Our respondents did not always distinguish between
different types of investigational or ‘experimental’ treat-
ments - between investigational drugs that are studied
by physician-researchers in clinical trials and will even-
tually be evaluated for marketing authorization on the
one hand, and ‘experimental’ treatments that are of-
fered by complementary and alternative healers, or by
quacks within the Netherlands or abroad, who are only
pretending to be medical doctors, on the other hand.
I felt like, before I go see a medical specialist, I’ll go
on looking for other options, first. I thought, it won’t
hurt to try. So I found a website of this natural
doctor […] and they offered medications. So I
thought: I’ll try it. So I went there. And they
examined everything, and you start with a type of
pill, one pill consisting of four small ones. And then
you start to build up the dosage, building up and
up. Until you observe change. (F2).
Respondents were also looking for treatment options
abroad that were not offered in the Netherlands. Patients
went to Germany, Belgium, the United Kingdom and
Turkey for diagnostic imaging, surgery, pharmaceutical
drugs or other treatments.
Some respondents reported their experiences with the
types of unapproved treatments we were looking for.
One respondent spoke about an investigational agent for
a chronic condition. This agent may have been approved
for another condition (the respondent did not know), so
this may have been an example of off-label use rather
than pre-approval access:
R. Did you swallow it or inject it?
R. No, you inject it, you inject it. I injected it instead of
[another drug].
R. Right.
R. And I had discovered it myself, on the internet,
because I was looking for something for someone else. I
don’t have to look for myself any longer, I know that by
now. But I thought: hey, this could be very interesting
for me, too.
I. And how did your doctor respond to this?
R. Well, I requested a meeting with my pulmonary
doctor. An in-between meeting. And well, it was an
internist, actually. And he said: ‘Oh, how good that
you found this out, because we are actually not
quite there yet. But I think you deserve it, because
you’ve done so much. Just to get yourself going
again.’ And then I just got it. I had to come back
every two weeks to get my blood tested, but it
worked much better than [the other drug]. (F4).
Reasons (not) to pursue non-standard treatment options
Respondents had very little personal experience with
expanded access, neither with compassionate use
programs nor with named-patient programs. In our
focus group discussions, respondents tended to speak
interchangeably about newly approved drugs, off-label
use of existing drugs, and investigational treatments
within or outside of the context of clinical trials. Pa-
tients sometimes could not tell the difference between
scientifically sound and unsound ‘new’ or ‘experimen-
tal’ treatments. When we noticed this, we explained
clearly that our study focused on drugs that were be-
ing studied by researchers in clinical trials. We asked
respondents to imagine that a clinical trial would be
ongoing in another European country, but not in the
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Netherlands, and that their treating physician could
request permission to import the investigational drug
through the named-patient program.
When asked under what conditions they would con-
sider trying an unapproved, investigational treatment,
respondents primarily mentioned conditions related to
the scientific basis for the treatment: the treatment
would have to be targeted at their particular disease,
there must be ‘enough information’ about the mech-
anism of the drug, its possible side effects, and inter-
actions with other drugs. One respondent indicated
that the drug would have to have been tested in hu-
man beings, not merely in animals. Respondents
wanted to know what the ‘measured effects’ of the in-
vestigational drug were on other patients, and what
other patients’ subjective experiences were with the
drug. One respondent said that she “would have to
be in a group,” (F4) so that she knew that other pa-
tients, too, had considered the treatment and opted
for trying. One respondent had heard about phases in
clinical drug research, and about a time lag between
marketing authorization and market availability, and
indicated to want to use a drug during that time lag.
Respondents were more willing to use unapproved
drugs that had already been approved in other coun-
tries. A respondent with a chronic condition said:
I wouldn’t swallow something if nothing is known
about it. Then you’d really be a guinea pig. But I think
that if it has been tested in another European Union
country and if some results are available.. Then I
assume, for European Union countries, that they are
aligned more or less […] Then it won’t differ so much
from the Netherlands, in terms of rules […] Then it
seems safe to me. (F2).
Secondly, respondents mentioned conditions related
to the setting. Some respondents would prefer partici-
pation in a clinical trial over expanded access. For
these respondents, there would have to be profes-
sional medical supervision and adequate monitoring;
throughout the study, the doctor would have to be
easily accessible, for instance through an emergency
telephone number. One respondent said that a re-
placement should be available in case the treating
physician fell ill. Also, the investigational treatment
would have to be reimbursed. One respondent, who
was talking about participation in a clinical trial,
thought it was important that the drugs would remain
available after completion of the trial: “Once I start it,
I want to be given the chance, if I think it’s better, to
keep it.” (F4).
Another important set of reasons for using investiga-
tional drugs was related to the health condition of
patients: “if it could help me lead a normal life”, or “if I
could be cured definitely, or at least if my symptoms
could be alleviated.” (F1) Some indicated that with their
current combinations of pharmaceutical treatments, they
were doing all right, and they would only interfere with
this precarious balance if their level of suffering in-
creased: “If I can lead a minimally or reasonably normal
life, I don’t need an investigational drug.” (F4) Others
said that they would be interested in trying different, less
painful or burdensome modes of administration for one
or more medications they were using. For example, pills
that could replace the (large) set of drugs that they were
currently taking on a daily basis, or treatments that
would have fewer adverse long-term effects or undesir-
able side effects.
Some said they would try investigational drugs - in or
outside of clinical trials - without thinking, “because I have
nothing to lose.” (F1) Respondents thought that patients
who were suffering from fatal diseases or cancer were
more likely to use investigational drugs than patients who
were suffering from chronic (combinations of) conditions.
Respondents generally agreed that the more despair they
were experiencing, the more likely they would be to try in-
vestigational treatments.
R. This sounds a bit weird, but the worse you’re doing,
the more you would want to go for even the smallest
chance.
R. The more you want to try. (F2).
Well, it won’t do much for me, because by now, I know
from this internist that it cannot be cured, not with
medications, not in any way. But in principle I would
do anything to be cured, whatever it takes. I would
start tonight. […] The pain that I know is going to
come tonight when I go to bed… I will be screaming
like a small child. Yes, well, that is a reason for me to
say: I’d try anything. (F3).
Apart from health reasons, respondents mentioned more
altruistic reasons to participate in clinical studies: “to find fit-
ting medications for myself and for others” (F2), for science,
for “the future” (F3), for future generations of patients.
The burdens and risks associated with participation in
clinical trials or usage of new drugs - whether approved
or not (yet) approved - were mentioned as a main reason
not to take part. Respondents were afraid of allergic re-
actions or complications, some because they had had
(serious) adverse reactions to drugs in the past. Patients
with chronic conditions said:
Well, I didn’t do it. Because I think, well, it’s that
exhaustion.. […] I didn’t feel up to it, because I would
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have to go to that hospital again and again, so I
steered clear from that. (F1).
It should not be at the expense of my own health. You
see, it shouldn’t like, affect my glucose levels, or cause
me to get more hypo[glycaemia]s. It should not come
at the cost of my health. I have become more and
more careful about my health. (F2).
Respondents were less willing to receive injections
than to take pills, and less willing to take pills than
to use creams. Also, respondents thought it was very
important that their primary care physician or their
treating medical specialist agreed with the investiga-
tional treatment. After all, it was felt, doctors had
more knowledge of biology, health and disease, and
they could point out possible adverse consequences.
However, others said they would want to discuss it
first with others - partners, children or parents - or
make their own decisions before asking the doctor’s
opinion.
One focus group participant, a young woman with me-
tastasized cancer, narrated that she was “given up” (FE) in
2007, but - after some deliberation - decided to take part
in a phase I clinical trial. Almost 10 years later, she was -
inexplicably - still alive and using the drug, through a
post-trial single-patient compassionate use program.
Despite the life-saving effect that the drug had on her, it
was no longer being studied for her condition, because of
disappointing results in the wider group of research par-
ticipants. When she was considering the option to take
part in the study in 2007, what made her decide to enroll
was the fact that she could always stop and withdraw
whenever she wanted:
You’ll get all sorts of information, also information to
take home. I was talking it over with [my husband].
We were thinking: what are we going to do? And we
decided, eventually, to just go for it, right? But the fact
that I could stop at all times, that was the decisive
factor. Like, if I’ll get to much discomfort at some
point, I can always quit. (FE).
The importance of being able to stop was stressed in
several focus groups. One respondent mentioned that an
‘antidote’ should ideally be available.
One respondent with incurable cancer narrated how
changes in his relationship with his son affected his
perspective on his own treatment. He became more
accepting of his nearing death, and less likely to try
investigational treatments:
Now I am much more relaxed than a year ago,
when I was still alert and eager to find something
that would give me more time to try and fix the
problems that we [father and son] had together.
And, well, so much calm has come into my life, just
because these important issues have been solved.
And there will always be other things, but I… I am
done, completely done. Oh, I will go on until my
tongue hangs out, as a manner of speaking. But
with a good feeling. (I3).
Some patients offered that it could be worthwhile,
for patients who have “nothing to lose” (I1) to allow
them to try investigational drugs earlier in the treat-
ment trajectory, not only after all else has failed.
When standard of care is associated with severe side
effects and known not to be effective (e.g. combin-
ation chemotherapy for certain oncological condi-
tions), patients may not find it acceptable to try
standard of care first. In the early stages of disease,
they prefer access to advanced treatments rather than
having to first undergo conventional treatments of
which the risk-benefit profile is better known, but not
attractive. One respondent with incurable cancer
recounted that his doctor had fought “by fire and
sword” to prescribe an investigational or off-label
treatment (the respondent did not know) before
standard of care:
We did it anyway. And it worked wonderfully well. My
[tumor marker] dived downwards. And it held
fantastically, for about a year. It was, well, super. (I3).
Patients’ expectations of physicians with regard to non-
standard treatment options
Patients whole-heartedly believed that it is the re-
sponsibility of treating physicians to inform their pa-
tients about the standard of care, but also about non-
standard treatment options, including referrals to ter-
tiary hospitals, clinical trials and opportunities for ex-
panded access to investigational treatments, in the
Netherlands or abroad. Respondents also assumed
that doctors, especially those working in university
medical centers or large (teaching) hospitals, were
aware and had up-to-date knowledge of investiga-
tional treatments and clinical trials, around the world.
Many respondents were aware of the existence of
continuing education requirements for physicians in
the Netherlands. Respondents recounted how they
thought that physicians working in university medical
centers attended scientific conferences, also abroad,
and how they would learn about new treatment op-
tions and ‘what is in the pipeline’ (FE). Also, patients
expected that doctors would propose investigational
treatments that might be beneficial if these were
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available. When asked whether respondents expected
their treating physicians to ‘look beyond’ for other
options when standard of care was exhausted or in-
sufficient, they said they did. It falls within the scope
of physician’s tasks or duties, it was felt, to inform
patients about treatment options that could poten-
tially benefit them, including expanded access.
R: I know from my quest on the internet, that there are
actually studies for my tumor type. But my doctor has
not mentioned them.
I: Did you expect that he would?
R: Yes, I guess I did. And to me that is a signal, right?
A lot of work will have to be done to make sure that
the patient gets all the information. (I5).
R. How far beyond is far beyond? […] There are
specialists who are more like: ‘I really listen to my
patient. My patient knows what he is feeling’, and they
will respond to that. And that really makes a
difference. Because you can go far beyond the basic
treatment protocols.
R. That is a big difference.
R. I think he should go as far as the patient wants.
R. Yes.
R. Yes, it’s the patient who should decide.
R. Yes.
R. Yeah, well, sometimes, you have to protect patients,
too. (F1).
Others, too, said that doctors must sometimes protect
their patients. When doctors have their doubts about a
particular investigational treatment, it was felt by some
respondents, they should not bring it up with their pa-
tients. Especially when treatments were potentially
harmful or could be detrimental to patients’ psycho-
logical wellbeing, those patients need not be informed
about such treatments. Respondents trusted that doctors
would not offer them anything that they believed would
pose unacceptable risks. Also, it was felt, doctors were
allowed to offer their own views, and, for instance, ac-
tively discourage investigational treatments, when based
upon adequate arguments.
R. But how do you know whether a doctor knows what
he’s talking about?
R. You don’t. (F2).
Some respondents thought, however, that even if doc-
tors have doubts about investigational treatments, they
should start a discussion about these options:
R. And this new doctor, she really brings everything to
the table when I’m there, and she’ll inform me about
these things.
I. And do you consider it to be her task, to do that?
R. Yes, yes, I do. Yes. Look, she..
R. I do, too.
R. She can totally say, I don’t believe in it, yet, or
whatever, but she should bring it up.
R. Yes.
R. I do find that she should start the discussion. (F4).
Some respondents narrated how they had discussed
with their doctors, in advance, what would happen when
the end of the standard treatment trajectory came in
sight, and some doctors indicated that they were willing
to resort to (further) non-standard treatment options
when necessary. Respondents appreciated this.
So we were talking about stopping this treatment,
eventually. And she said: ‘I’m going to go see what
we can do, right, things beyond the kinds of things
that are going to be on the shelves by then. But
when that time comes, right, I will go and look for
you.’ So she really indicated, like, she would go out
of her way… (FE).
In spite of the information we provided, some respon-
dents did not seem to understand the existing regulatory
frameworks for expanded access, and believed that it is
illegal. When asked whether respondents in one focus
group thought that medical specialists should try and re-
quest expanded access for individual patients, they said:
R. Yes.
R. Yes, if a patient wants to try something.. Give him a
chance.
R. Yeah, well, I am doubtful whether the primary care
physician, or any doctor, has any say in these matters.
R. I don’t think so.
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R. I don’t think so either.
R. I think that he will be called to order by the
government.
R. I think so, too. (F2).
Reimbursement of non-standard treatment options
When patients have exhausted standard treatment op-
tions, it was felt by our expert patients, many doctors
in the Netherlands do not propose non-standard
treatment options. Reimbursement, or rather the lack
thereof, according to expert patients, was one of the
main reasons why doctors refrained from pursuing
expanded access. One respondent talked about new
surgical interventions:
Well, these minimally invasive treatments, these I find
a wonderful addition to the package [of standard
treatment options] that we’ve already got. And what
[we] have been working on, is saying: well, many of the
oncologists will not mention this to patients, because
one of the reasons why they won’t mention it, is that it
is not covered by basic health insurance policies. (I4).
Respondents felt that there are disparities among pa-
tient groups with regard to access to good-quality health
care, and considered these unjust. Patients who are more
assertive, health literate, affluent and/or resourceful
could get access to treatments - or reimbursement of
treatments - that others could not. One respondent told
the group that although she did not have much money,
she did have a big mouth:
I have been very much at odds with my healthcare
insurer, because these pills cost 365 euros or
something, for two and a half months. And, well, I just
cannot afford that. And eventually I acted on it, I
wrote the House of Representatives, I wrote everybody.
When I finally got [a regional television network]
involved, and, well, the same day [the insurance
company] gave me my medicines back. (F1).
Respondents were generally very willing to pay for in-
vestigational treatments, if they had to. Even if the inves-
tigational treatment were very expensive, they would try
and find alternative means to obtain the drug.
R. If I could get something illegally, or buy something,
that would really work, well, I’d sell something, so that
I could make sure that I’d be able to buy it.
R. Yes, I agree.
R. Me, too. I’d find a way.
[…]
I. But what if it would be very expensive?
R. I’d still do it.
R. Would you?
R. Yes. […].
R. But don’t you think that the healthcare insurer
should pay for it?
R. I do, actually. But they won’t. (F2).
A respondent who was disabled, alone and suffering
from terrible pains, explains:
My daughter, she has a very important position, she
informed in [a far-away country], when I was just di-
agnosed. And they have a machine there, and you go
in for three weeks. And it purifies the blood or some-
thing, anyway, when you come out, you’re perfectly
healthy. But it costs 150,000 euros. […] So that is the
story. I could have been cured, but I didn’t have the
money. And now I’ve been stuck with this for ten years
or so. (F3).
Expert patients thought it was unethical to have pa-
tients pay for investigational treatments themselves.
They thought that health insurers or the state should re-
imburse investigational treatments. One patient told us
about an investigational treatment that he had been
given abroad, which is four times less expensive than
standard of care for his condition in the Netherlands,
and, according to the respondent, more effective (I1).
While his healthcare insurer supported future inclusion
of the investigational treatment in the Dutch national
basic healthcare insurance package in lieu of (much
more expensive) existing standard of care, it was not
willing to reimburse the costs of this patient’s treatment
abroad.
Patients who had gone abroad to try investigational
treatments reported that the expenses were worthwhile,
that they benefited somehow, or for some time, and did
not regret their decisions. But these decisions clearly did
come at a cost:
Look, it has cost me 20,000 euros, and it has been
worth it. So now I’ve sold my house. Because I’m
thinking: well, if I can get a treatment somewhere that
I’ll have to pay for myself, I want to have money in the
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bank. And my children say it, too: ‘We’d rather have a
living mother in a rental apartment than a dead
mother in a privately owned house.’ (I1).
Another respondent had the means to go to a nearby
country to try an investigational treatment, but acknowl-
edged - and found problematic - that many other pa-
tients with the same condition were not able to afford
such medical travel.
I am in the lucky position that I can afford doing crazy
things, doing these things on my own initiative,
financially. This [investigational procedure] costs 6000
euros per treatment. […] But now it’s time for the next
step. I am working with [a hospital in the
Netherlands] to raise funds, because they are looking
for fifty or so research participants [to validate the
treatment], and they don’t have any budget. And the
painful thing about this situation is, I get phone calls
from one or two people every day, who have read [an
interview with this patient about this treatment
abroad], who want to know more about it. […] I think
it is unacceptable, in fact, that this happens, that I,
incidentally, can afford this, while all of the others
cannot. I don’t feel good about this. […] You want
these things to be accessible for everybody. (I3).
Discussion
This qualitative study was the first to provide insight
into what patients with unmet medical needs want
with regard to unapproved, investigational treatment
options, and what they expect from their treating
physicians. Our findings show that patients with un-
met medical needs in the Netherlands have very lim-
ited knowledge about and experience with expanded
access. However, many – but not all – of our respon-
dents were well informed and ‘empowered’ with re-
gard to their own health condition and medical care.
Some patients were very knowledgeable about their
conditions and/or active in their respective patient
communities, which may have led them to have dif-
ferent experiences and views than patients who were
less informed and/or less active. The idea that pa-
tients must be assertive in order to get access to best
available care was widely expressed and supported by
our respondents. Based on our findings, five areas of
ethical concern can be discerned.
First, when patients have exhausted standard treat-
ment options, they may start looking for other non-
standard options. Patients are finding their way to open
access publications of clinical trials on the internet, and
especially some of those who suffer from rare, chronic
or long-term progressive disorders are becoming
knowledgeable about their conditions [19], about stand-
ard of care, and about ongoing clinical trials in their
own country or abroad. However, this does not apply to
the majority of patients. Many of our respondents had
little knowledge of systems for drug development, clin-
ical trials, marketing approval by drug regulatory author-
ities and/or health technology assessment and
reimbursement policies. Some respondents were unable
to distinguish between new drug treatments that were
under investigation by healthcare professionals in aca-
demic hospitals on the one hand, and ‘experimental’
complementary or alternative treatments on the other
hand. Patients often did not know whether the drugs
they took were approved for their indication, for other
indications (off-label use), or not at all. It has been ob-
served that expanded access, so far, has remained limited
to patients who were well-off and/or influential and
whose partners or close friends were expert medical spe-
cialists [1, 3, 20]. Our study confirms the existence of
disparities along the lines of health literacy and connect-
edness, raising concerns with regard to equal access to
non-standard treatment options.
Second, our respondents stressed that decisions with
regard to (non-standard) treatment were ‘highly per-
sonal’ in nature. Patients were not unequivocally willing
to try new drugs. Rather, they had nuanced views with
regard to investigational drugs, explaining their willing-
ness to take part in expanded access in terms of factors
related to the scientific evidence of the safety and effi-
cacy of the drug (e.g. respondents were hesitant about
first-in-human studies) and factors related to the
organization of health care surrounding the use of an in-
vestigational drug (e.g. the treating physician would need
to be involved; they would need to be monitored
closely). Also, many patients with chronic conditions
were afraid to disturb what they perceived to be a pre-
cious equilibrium that they were able to maintain with
their current combinations of drugs and lifestyle adjust-
ments, and as long as they felt ‘okay’, they were reluctant
to try something new. This is consistent with earlier re-
ports on oncology patients in the Netherlands, for in-
stance, who refused to participate in phase I trials
because of low expectations of benefit, concerns about
side effects, and their negative effects on the patient’s
current - and, for the time, acceptable - condition [15].
However, patients with a life-threatening disease who
had run out of standard treatment options and were suf-
fering from refractory symptoms, were less hesitant to
try investigational drugs. Patients with chronic condi-
tions and patients with life-threatening conditions thus
seemed to differ in their readiness to try investigational
drugs. The fewer patients’ options and the greater their
despair, the greater was their willingness to pursue the
use of non-standard treatment options.
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Third, patients volunteered many stories about their
general experiences with medical specialists. Although
some patients reported negative experiences with
medical specialists, most had high levels of trust in
their doctors and high expectations of their doctors.
Patients expected, for instance, that doctors are well
aware of scientific developments in their fields, and of
new treatments being studied around the world. They
believed that doctors would inform them about all
treatment options, including those that are not ap-
proved for marketing and still under investigation,
and including those that are available only in other
hospitals or even countries. They expected that doc-
tors would actively look for non-standard treatment
options when standard treatment options were
exhausted, and, importantly, they considered it to be
a doctor’s duty to do so. Some respondents indicated
that they would try investigational drugs only if their
doctor recommended and/or supported it. In spite of
prevailing ideals of patients’ self-management and
shared decision-making, doctors continue to have a
decisive role in determining their patients’ treatments.
It is important to note that contrary to patients’ ex-
pectations, doctors do not always mention clinical tri-
als [21], and, as our study indicates, will rarely
mention existing opportunities for expanded access.
Fourth, patients with chronic conditions and/or un-
met medical needs showed a high willingness to pay
for unapproved, investigational drugs. Few respon-
dents said that they had ethical problems with having
to pay out of pocket for non-standard treatment op-
tions: it was felt that one’s health is so important that
it trumps other priorities, and that one will have to
find other ways to fund the treatment, such as crowd
funding. More and more patients resort to online pe-
titions and social media campaigns [22], raising eth-
ical concerns [23]; campaigns may not always
succeed, and success may not be fairly distributed
among patients. Even if patients succeed in amassing
the funds, private money does not always buy them
drugs. In most hospitals in the Netherlands, it is gen-
erally not considered morally acceptable to receive
out-of-pocket payments from patients for ‘extra’ (non-
standard) health services; in most cases, either the
health insurer agrees to reimburse the treatment (out
of leniency), or the treatment is simply not provided.
Health insurers will typically not reimburse investiga-
tional drugs, because scientific evidence of its effect-
iveness is often lacking. Thus, investigational drugs
would need to be supplied by the pharmaceutical
company at no cost, ‘out of compassion’. Companies,
however, may not always be willing or able to do so.
Thus, as the options in the Netherlands may be lim-
ited, some Dutch patients are using private or
otherwise collected funds (e.g. crowd funding) to seek
new treatment options abroad [24].
Either way, respondents in our expert patient focus
group found it unacceptable to let patients pay them-
selves. They felt that the development of a transparent
and equal funding system for expanded access should be
a priority for policy makers. For instance, it was sug-
gested, governments, health insurers and drug devel-
opers could each contribute to a fund dedicated to cover
the costs of investigational drugs for patients who are
eligible for expanded access. In the international litera-
ture on expanded access, alternative funding arrange-
ments are being considered, including the setting up of
foundations or non-profit organizations as intermediar-
ies [25].
Fifth and finally, our findings suggest that although ex-
panded access may benefit patients (one respondent was
kept alive by an investigational drug), it may also harm
them, in various ways. One of the most prominent eth-
ical issues in the literature on expanded access is the
question of false hope [26, 27]. When the chance at
medical benefit is very slim, will not the sheer existence
of opportunities for expanded access lead to false hope
among patients who are dying? One interviewee narrated
how she had sold her house in pursuit of a cure, to fund
trips abroad for investigational treatments. This patient
may spend all her money on treatments that are not
likely to take away her illness. She was still alive, how-
ever, in spite of her Dutch treating physician’s expecta-
tions. Our respondents seemed to understand that there
are risks associated with the use of an investigational
agent, the safety and efficacy of which will not have been
fully established. Some of these risks are unknown and
unquantifiable, which makes it difficult to make in-
formed decisions whether or not to proceed with
requesting access. When asked how they would make
such decisions, respondents with chronic conditions
were well aware of everything they stood to lose, were
careful to avoid side effects, and not to needlessly im-
peril a precarious health equilibrium or an acceptable
quality of life. Respondents said that in the face of life-
threatening illness, however, they would take more risks
and be more willing try an investigational drug with a
small chance at medical benefit. Thus, patients who are
facing death may be more vulnerable to high hopes and
(financial) exploitation.
In the future, ethical discussions on expanded access
should focus on three areas: first, strengthening of
decision-making and informed consent processes by pa-
tients with life-threatening disease, and on the blurry
line between hope and false hope; second, addressing
the disparities in access to investigational treatments
across patients groups of varying levels of health literacy
and assertiveness; and third, addressing the gap between
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patients’ expectations of their treating physicians and the
existing reality in which doctors may have limited aware-
ness of opportunities for expanded access and may not
recognize a ‘duty’ to provide information about ex-
panded access to patients who run out of standard treat-
ment options.
Limitations
While we found expert patients to be highly moti-
vated to take part in our qualitative study, it was dif-
ficult to recruit respondents who were more
representative of the Dutch general population of pa-
tients with chronic conditions or unmet medical
needs. With the help of a recruitment agency, we
were able to engage respondents who were diverse in
terms of age, gender, educational background and
health literacy. Still, our respondents were rather as-
sertive with regard to their health, and may have dif-
fered in this respect from other Dutch patients.
Studies have found, for instance, that most patients
are not actively looking for non-standard treatment
options such as clinical trials, and tend to follow rec-
ommendations by their doctors instead [21, 28, 29].
Our respondents were generally less passive, and
more actively involved in searching for and decision-
making regarding treatment options. Concerns regard-
ing the introduction of bias through the engagement
of atypical patients in research have been documented
[30], and may limit the generalizability of our find-
ings. Further empirical research efforts may need to
focus on mapping patients’ experiences and views
across different patients groups and disease groups.
Patients may differ in level of understanding, but also
in terms of relevant personality traits, such as willing-
ness to take risks, which may lead them to have dif-
ferent needs regarding, for instance, information
provision about expanded access.
Moreover, at the outset of our research project, we
meant to include patients who were running out of
standard treatment options and considering the use of
investigational drugs, or patients who had used investi-
gational treatments in the past. However, such patients
were difficult, if not impossible, to find, given the very
low uptake of opportunities for expanded access in the
Netherlands. While we did talk informally to patients
who had ALS or metastasized melanoma, we did not
want to recruit them for audiotaped interviews or focus
groups, because they were very ill and potentially life-
saving treatment options were at the time not available
to them.
In addition, there are particularities of the Dutch
health care system, such as the relative infrequency of
malpractice litigation, the ‘conservative medicine’ atti-
tude of primary care physicians, aimed at avoiding over-
diagnosis and overtreatment (although Dutch general
practitioners report that they satisfy patients’ demands
for referral too easily, resulting in patients receiving ‘too
much’ care in hospitals) [31], and the system of universal
health coverage and mandatory health insurance, which
may limit the external validity of our study. Policy dis-
cussions on expanded access would thus benefit from
further qualitative studies of patients’ experiences con-
ducted in other countries.
Finally, many of the ethical issues raised, including in-
formed consent, the risk of exploitation, the notion of
false hope, potential medical and psychosocial harms,
funding issues and equal access, merit further normative
scrutiny.
Conclusion
Our respondents, Dutch patients suffering from a
range of serious, chronic, rare, progressive and/or life-
threatening diseases, were assertive and actively look-
ing for other non-standard treatment options. Never-
theless, they had very little knowledge about and
personal experience with unapproved, investigational
drugs outside the context of clinical trials. When
asked under what conditions they would try investiga-
tional treatments, they mentioned highly personal
considerations ranging from the level of available evi-
dence to the active involvement of their treating
physician, and from potential interactions with their
current medications to the mode of administration.
Patients were generally protective of their quality of
life and current management of their medical condi-
tion(s), and would try investigational drugs only when
they suffered, ran out of options, and had little left to
lose. These findings strengthen the notion that (at
least some) patients with chronic conditions are cap-
able of making well-considered choices with regard to
the use of investigational drugs. Patients with life-
threatening illness, however, are more willing to take
risks and try investigational drugs, even in the context
of a small chance at medical benefit. Also, when pa-
tients are confronting death, they are more willing to
spend private money on investigational drugs. In this
patient group, the blurry line between hope (against a
small chance at medical benefit) and ‘false hope’
should be studied and addressed.
Over the next couple of years, physicians, pharmaceut-
ical companies, and policy-makers will be shaping pol-
icies and practices of expanded access. In doing so, they
should be responsive to patients’ views and concerns.
Patients might expect their treating physicians to inform
them about investigational treatments when the end of a
standard treatment trajectory comes into view, even if
their chances at cure, prolongation of life, or improve-
ment of quality of life are slim. Also, patients with
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unmet medical needs - especially those with life-
threatening disease - might be willing to pay a high price
for a small chance at medical benefit, which might ren-
der them vulnerable to exploitation. This concern might
especially be relevant to healthcare systems in which fair
and transparent funding arrangements are lacking for
expanded access.
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